Page 147 - CIBERER-2015-eng

Most relevant scientific articles
Research Groups
EgusquiaguirrE sP, Manguán-garcía c, Pintado-BErn- inchEs L, iarriccio L, carBajo d, aLBEricio F, royo M, PEdraz jL, hErnándEz rM, PErona r, igartua M. De- velopment of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a prom- ising approach for the treatment of defective telomer- ase disorders. . Eur J Pharm Biopharm. 2015 Apr;91:91- 102. doi: 10.1016/j.ejpb.2015.01.028. Epub 2015 Feb 7. PMID:25660910.
Telomerase Activity, Cell Proliferation and Reduces DNA Damage, Oxidative Stress and Cell Senescence in Dysker- in Mutant Cells. PLoS One. 2015 Nov 16;10(11):e0142980. doi: 10.1371/journal.pone.0142980. eCollection 2015. PMID: 2657138.
BEnitEz-BuELga c, sánchEz-Barroso L, gaLLardo M, aPELLániz-ruiz M, ingLada-PérEz L, Et aL. Impact of chemotherapy on telomere length in sporadic and famil- ial breast cancer patients. Breast Cancer Res Treat. 2015
caLvEtE o, MartínEz P, garcía-Pavia P, BEnitEz-BuELga c, PauMard-hErnándEz B, FErnándEz v, Et aL. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.Nat Commun. 2015 Sep 25;6:8383. doi: 10.1038/ncomms9383. PMID: 26403419.
iarriccio L, Manguán-garcía c, Pintado-BErninchEs L, ManchEño jM, MoLina a, PErona r, sastrE L. GSE4, a Small Dyskerin- and GSE24.2-Related Peptide, Induces
Highlights
PATENTS:
Método para predecir la respuesta al tratamiento con radioterapia combinada con quimioterapia basada en cisplatino. Application No. P2011330783. Inventors: Inmaculada Ibañez de Cáceres, Rosario Perona, Cristobal Belda-Iniesta, Olga Pernía y María Cortes Sempere. Presentation date: May 9, 2013. Interna- tional Phase, USA (2015).
Péptidos Derivados de GSE24.2 para Tratar Enferme- dades Producidas por Estrés Oxidativo y Daño al ADN. P201331573, Presentation date: October 25, 2013. Inventors: Rosario Perona, Leandro Sastre, Laura Pintado Berninches, Jaime Carrillo García, Antonio Molina Pachón, Laura Iarriccio Silva y Cristina Man- guan García. PCT presented. International phase. Licence to Advanced Medical Projects.
Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21. PMID: 25528024.
LóPEz-ayLLón Bd, dE castro-carPEño j, rodríguEz c, PErnía o, iBañEz dE cácErEs i, BELda-iniEsta c, PEro- na r, sastrE L. Biomarkers of erlotinib response in non- small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. Int J Clin Exp Pathol. 2015 Mar 1;8(3):2888-98. eCollection 2015. PMID: 2604.
THESIS
Mecanismos reguladores de las células madre neu- ronales: implicación en los procesos de envejec- imiento y cáncer. Olatz Arrizabalaga Garde. Apto Cum laude, 2015).
PROJECTS
1-Estudio Molecular integrado en CNMP. Búsqueda de marcadores moleculares pronósticos, heteroge- neidad de células circulantes tumorales y sensibili- dad extrema a tratamiento. Inv. Principal. R. Perona. FIS PI14/01495. Duration 2015-2018.
RESULTS
In collaboration with Advanced Medical Projects and a US Pharma dedicated to rare diseases we are performing the preclinical assays (efficiency, bio- distribution, toxicity, efficacy in animal models and cells derived from patients) for the therapeutic appli- cation and clinical trials of PLGA/PEI nanoparticles loaded with the peptide GSE4 for the treatment of dyskeratosis congenita and idiopathic pulmonary fibrosis.
Institution: Agencia Estatal Consejo Superior de Investigaciones Científicas
Contact: Instituto de Investigaciones Biomédicas Alberto Sols · C/ Arturo Duperier, 4. 28029 MADRID Tel.: 91 585 44 63 · E.mail: [email protected]
CIBERER I Annual report 2015 I 147